Ultragenyx Pharmaceutical Inc.
60 Leveroni Court
Novato
California
94949
United States
Tel: 415-483-8800
Fax: 415-483-8810
Website: http://www.ultragenyx.com/careers/
Email: info@ultragenyx.com
447 articles about Ultragenyx Pharmaceutical Inc.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 19, 2024
4/19/2024
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 44,965 restricted stock units of the company’s common stock to 14 newly hired non-executive officers of the company.
-
In a Phase I/II study, Ultragenyx’s antisense oligonucleotide GTX-102 led to significant cognitive, behavioral, sleep and gross motor improvements in patients with the rare genetic disorder Angelman syndrome.
-
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
4/15/2024
Ultragenyx Pharmaceutical Inc. announced new data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome.
-
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
4/12/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the conference call to discuss new clinical efficacy and safety data from the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome that will be presented at the American Academy of Neurology Meeting (AAN), will now be taking place on Monday, April 15, 2024 at 8 a.m. Eastern Time (ET).
-
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
4/12/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that preclinical and clinical data, including new clinical efficacy and safety data from the expansion cohorts in the Phase 1/2 study of GTX-102 for the treatment of Angelman syndrome, will be presented at the 76th Annual American Academy of Neurology Meeting (AAN) being held April 13-18 in Denver and virtually.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - March 22, 2024
3/22/2024
Ultragenyx Pharmaceutical Inc. reported the grant of 13,020 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.
-
Ultragenyx to Participate at Investor Conferences in March 2024
2/27/2024
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, announced that management will be participating in three upcoming investor conferences.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 23, 2024
2/23/2024
Ultragenyx Pharmaceutical Inc. reported the grant of 10,995 restricted stock units of the company’s common stock to nine newly hired non-executive officers of the company.
-
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
2/15/2024
Ultragenyx Pharmaceutical Inc. reported its financial results for the quarter and full year ended December 31, 2023 and reaffirmed its financial guidance for 2024.
-
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update
2/8/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 15, 2024, to discuss its financial results and corporate update for the fourth quarter and the year ending December 31, 2023.
-
Ultragenyx Announces Data Demonstrating Treatment with UX111
2/6/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced data demonstrating treatment with UX111 (ABO-102) AAV gene therapy resulted in rapid and sustained decreased levels of heparan sulfate (HS) in cerebrospinal fluid (CSF) in patients with Sanfilippo syndrome type A (MPS IIIA).
-
Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
2/5/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to GTX-102 for the treatment of Angelman syndrome (AS).
-
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
1/25/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been dosed with UX701 across the three dose-escalation cohorts in Stage 1 of its pivotal Phase 1/2/3 Cyprus2+ study.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Jan 19, 2024
1/19/2024
Ultragenyx Pharmaceutical Inc. reported the grant of 12,130 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.
-
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones
1/7/2024
Ultragenyx Pharmaceutical Inc. reported preliminary unaudited 2023 revenue results, cash and investments at year end 2023, and provided 2024 guidance on select key financial metrics including net cash used in operations.
-
Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
1/4/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the National Institute for Health and Care Excellence (NICE) has issued a final draft guidance recommending Evkeeza® (evinacumab) to NHS England.
-
Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome
1/3/2024
Ultragenyx Pharmaceutical Inc. today announced the completion of patient enrollment in its Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome (AS).
-
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 PM PT.
-
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 21, 2023
12/21/2023
Ultragenyx Pharmaceutical Inc. reported the grant of 30,325 restricted stock units of the company’s common stock to eight newly hired non-executive officers of the company.
-
Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)
12/18/2023
Ultragenyx Pharmaceutical Inc. announced that the European Commission has extended the approval of Evkeeza® as an adjunct to diet and other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia.